Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

Abstract

The rigorous conduct of well designed clinical trials is critical to improving outcomes for patients with gynaecological cancers. The Gynecologic Cancer InterGroup (GCIG) has promoted collaboration and harmonisation to guide clinical trials in ovarian and endometrial cancer through a series of consensus meetings with published statements. GCIG convened the inaugural Cervical Cancer Consensus Conference in Clinical Research in Dublin, Ireland, on Oct 14-15, 2024, to develop a consensus on design elements, essential questions, and unmet needs in cervical cancer research. All 33 GCIG member groups and additional representatives from patient advocates, young investigators, investigators from low-income and middle-income countries, and the Cervical Cancer Research Network participated in developing, refining, and adopting 16 statements within four topic groups: diagnosis and staging, early-stage disease, locally advanced disease, and persistent or recurrent disease. Consensus was obtained for all statements. Areas of unmet need were identified and tabulated. The high agreement rates generated through a process of debates, discussions, and consensus represent a positive commitment that incorporates harmonisation, inclusion, and pragmatism in the conduct of academic clinical trials globally.